Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Other Accumulated Expenses: 2023-2024

Historic Other Accumulated Expenses for Zenas BioPharma (ZBIO) over the last 2 years, with Dec 2024 value amounting to $249,000.

  • Zenas BioPharma's Other Accumulated Expenses rose 74.70% to $580,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $580,000, marking a year-over-year increase of 74.70%. This contributed to the annual value of $249,000 for FY2024, which is 134.91% up from last year.
  • Per Zenas BioPharma's latest filing, its Other Accumulated Expenses stood at $249,000 for FY2024, which was up 134.91% from $106,000 recorded in FY2023.
  • Zenas BioPharma's Other Accumulated Expenses' 5-year high stood at $249,000 during FY2024, with a 5-year trough of $106,000 in FY2023.
  • In the last 2 years, Zenas BioPharma's Other Accumulated Expenses had a median value of $177,500 in 2023 and averaged $177,500.
  • Data for Zenas BioPharma's Other Accumulated Expenses shows a peak YoY surged of 134.91% (in 2024) over the last 5 years.
  • Over the past 2 years, Zenas BioPharma's Other Accumulated Expenses (Yearly) stood at $106,000 in 2023, then skyrocketed by 134.91% to $249,000 in 2024.